arrow
L

Laura Pizzuti

irccs istituti fisioterapici ospitalieri (ifo)
H指数:36
被引数:4,025

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B (vol 23, pg 1379, 2022)

I型ifn通过触发表观遗传调节因子KDM1B促进癌细胞干细胞性 (第23卷,1379页,2022页)

2024-09-170
OAAI
Breast and cervical cancer in transgender men: literature review and a case report

跨性别男性乳腺癌和宫颈癌: 文献回顾和病例报告

2024-08-100
OAAI
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

DARPP-32和t-darpp在anti-HER2药物抗性发展中的作用。STEP研究的临床前证据

2023-11-011
OAAI
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

HER2-positive乳腺癌患者新辅助化疗加或不加帕妥珠单抗后的病理反应和生存率: Neopearl全国合作研究

2023-06-271
OAAI
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
Sexual dysfunctions in breast cancer patients: evidence in context

乳腺癌患者的性功能障碍: 背景证据

2023-04-188
OA
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study

新型冠状病毒肺炎爆发后晚期乳腺癌发病率上升。来自意大利covid-delay研究的真实数据

BREAST
IF7.9
2022-10-0116
OAAI
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

I型ifn通过触发表观遗传调节因子KDM1B促进癌细胞干细胞性

2022-08-2467
OAAI
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

CDK4/6抑制剂Ribociclib在局部晚期和寡转移性激素受体阳性,Her2阴性,晚期乳腺癌中的作用: 病例系列和文献复习

2022-02-092
OAAI
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

氟维司群和曲妥珠单抗在管腔HER2-positive晚期乳腺癌 (ABC) 患者中的应用: 意大利真实世界的经验 (HERMIONE 9)

2021-08-273
PREAI
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

基于MicroRNA的签名影响卵巢癌的临床过程和生物学: 一项miRNOmics研究

2021-07-1313
OAAI
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

管腔型乳腺癌中性粒细胞与淋巴细胞比值 (NLR) 的预后相关性: 新辅助治疗的回顾性分析

CELLS
IF5.2
2021-07-0324
OAAI
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

ChangeHER试验中转移性乳腺癌HER2-positivity增益的预后相关性

2021-07-026
OAAI
Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives

口咽和宫颈癌管理中的循环HPV DNA: 当前知识和未来前景

2021-04-0627
OAAI
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives

免疫检查点抑制过程中糖皮质激素使用的姑息和非姑息适应症。当前的证据和未来的前景

2021-01-0111
PREAI
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

三阴性转移性乳腺癌患者的二线Eribulin。多中心回顾性研究: 俄罗斯方块试验

2021-01-017
OAAI